Osteoarthritis (OA) is one of the largest unmet medical needs on the planet — a $393 billion global problem with no approved disease-modifying therapies.
So why hasn’t Big Pharma solved it?
Because they’ve all tried the wrong approach.
💸 Billions Spent. Zero Wins.
Over the last two decades, nearly every major pharmaceutical company has launched a program to stop cartilage degradation — and failed:
- Roche’s Cipemastat was abandoned after safety concerns in early trials.
- Procter & Gamble’s PG-116800 failed in humans after showing cartilage damage in animal studies.
- Galapagos & Servier’s GLPG1972 couldn’t show any meaningful benefit in a 400+ patient Phase 2b trial.
- Pfizer, Medivir, AstraZeneca, Wyeth, Merck, Novartis — the list of discontinued MMP, ADAMTS, and Cathepsin inhibitors is long… and expensive.
What went wrong?
⚠️ Too Narrow. Too Toxic. Too Weak.
Big Pharma focused on single-enzyme targets like MMP-13 or ADAMTS-5 — hoping one drug could block one pathway. But OA is a multifactorial disease, involving a cascade of proteases, inflammatory cytokines, and tissue destruction.
Worse, most of these drug candidates were small molecules with poor selectivity — meaning they caused off-target effects or systemic toxicity. That’s why so many of them failed in preclinical or Phase 1 trials.
🔬 Why CYT-108 Is Built to Succeed
Cytonics is not following the same flawed roadmap. We’ve taken a radically different approach:
- Multi-Target Strategy: CYT-108 is a recombinant version of a naturally occurring protease inhibitor that neutralizes dozens of destructive enzymes.
- Localized Action: Delivered directly into the joint space, CYT-108 works where it’s needed — without systemic exposure or immune activation.
- Clinically De-Risked: Over 10,000 patients have already been treated with APIC™, our first-generation A2M therapy. CYT-108 builds on this platform with enhanced potency and IP protection.
🧠 What It Means for Investors
Big Pharma’s failures weren’t due to lack of resources. They were caused by poor biological assumptions and bad design choices.
Cytonics is different.
We’ve validated the science. We’ve cleared Phase 1. And now we’re raising funds to begin a Phase 2 study that could finally deliver what Big Pharma couldn’t.
And now, we have over 8,000 shareholders who are backing a smarter approach to solving OA… one that’s rooted in biology, backed by patents, and designed to change the game.
